VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Tuesday, December 30, 2025

Stock Comparison

Allegion Public Limited Company vs Bio-Rad Laboratories, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Allegion Public Limited Company

ALLE · New York Stock Exchange

Market cap (USD)
SectorIndustrials
CountryIE
Data as of2025-12-26
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Allegion Public Limited Company's moat claims, evidence, and risks.

View ALLE analysis

Bio-Rad Laboratories, Inc.

BIO · New York Stock Exchange

Market cap (USD)
SectorHealthcare
CountryUS
Data as of2025-12-30
Moat score
61/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Bio-Rad Laboratories, Inc.'s moat claims, evidence, and risks.

View BIO analysis

Comparison highlights

  • Moat score gap: Allegion Public Limited Company leads (64 / 100 vs 61 / 100 for Bio-Rad Laboratories, Inc.).
  • Segment focus: Allegion Public Limited Company has 2 segments (79.9% in Allegion Americas); Bio-Rad Laboratories, Inc. has 2 segments (59.9% in Clinical Diagnostics).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
  • Moat breadth: Allegion Public Limited Company has 6 moat types across 3 domains; Bio-Rad Laboratories, Inc. has 6 across 3.

Primary market context

Allegion Public Limited Company

Allegion Americas

Market

Security products, access solutions, and related services (mechanical + electronic) in North America

Geography

North America

Customer

Commercial, institutional, and residential facilities; channel partners (distributors, installers, retailers)

Role

Manufacturer/brand owner; sells via distribution/retail; provides services and some SaaS

Revenue share

79.9%

Bio-Rad Laboratories, Inc.

Clinical Diagnostics

Market

In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls

Geography

Global

Customer

Hospital laboratories; diagnostic reference laboratories; transfusion laboratories; physician office laboratories

Role

IVD OEM / installed-base consumables supplier (systems + kits + controls)

Revenue share

59.9%

Side-by-side metrics

Allegion Public Limited Company
Bio-Rad Laboratories, Inc.
Ticker / Exchange
ALLE - New York Stock Exchange
BIO - New York Stock Exchange
Market cap (USD)
n/a
n/a
Sector
Industrials
Healthcare
HQ country
IE
US
Primary segment
Allegion Americas
Clinical Diagnostics
Market structure
Competitive
Oligopoly
Market share
n/a
9%-11% (implied)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
64 / 100
61 / 100
Moat domains
Demand, Supply, Legal
Supply, Demand, Legal
Last update
2025-12-26
2025-12-30

Moat coverage

Shared moat types

Distribution ControlCompliance Advantage

Allegion Public Limited Company strengths

Design In QualificationBrand TrustService Field NetworkData Workflow Lockin

Bio-Rad Laboratories, Inc. strengths

Scope EconomiesCapex Knowhow ScaleInstalled Base ConsumablesSwitching Costs General

Segment mix

Allegion Public Limited Company segments

Full profile >

Allegion Americas

Competitive

79.9%

Allegion International

Competitive

20.1%

Bio-Rad Laboratories, Inc. segments

Full profile >

Life Science

Competitive

40.1%

Clinical Diagnostics

Oligopoly

59.9%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.